Clinical trials: Disseminated Sclerosis
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of the study is to further evaluate the long-term safety and tolerability profiles of BG00002 (natalizumab) in Japanese participants with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01416155
- Testing
- natalizumab
- Where
- 22 sites in Japan
- Volunteers
- 97 people
- Sponsor
- Biogen
Multiple Sclerosis
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01093326
- Testing
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 353 people
- Sponsor
- Actelion
Multiple Sclerosis
Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS
This study will seek to determine the benefits that FES-LE cycling has over cycling alone on walking performance and quality of life in people with multiple sclerosis.
- Trial name
- MSCycling (NCT02606604)
- Testing
- RT 300: Lower Extremity Cycling
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stony Brook University
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-Remitting
Rehabilitation Study in MS Patients
Studying the effectiveness of a functional rehabilitation protocol (FRP) in early Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with Betaferon by comparing the physical ability of patients with and without FRP.
- Trial name
- NCT00780455
- Testing
- Interferon beta-1b, FRP within 15 days after randomization, Interferon beta-1b, FRP about 6 weeks after randomization
- Where
- 10 sites in France
- Volunteers
- 4 people
- Sponsor
- Bayer
Detrusor Muscle Hyperactivity
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects…
- Trial name
- NCT01357980
- Testing
- Botulinum toxin type A
- Where
- 17 sites in Czechia, France and 3 more
- Volunteers
- 47 people
- Sponsor
- Ipsen
Multiple Sclerosis
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Primary Objective: Assess the antibody response to influenza vaccine in patients with relapsing form of multiple sclerosis (RMS) treated with teriflunomide compared to a reference population.
- Trial name
- TERIVA (NCT01403376)
- Testing
- teriflunomide, Interferon-β-1, Influenza vaccine
- Where
- 14 sites in Austria, Canada and 3 more
- Volunteers
- 128 people
- Sponsor
- Sanofi
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
tDCS and Glucose Uptake in Leg Muscles
This study is to examine the efficacy of tDCS to improving walking in people with Multiple Sclerosis (PwMS). Our study compromises 1 group of subjects with MS which will attend the lab for three sessions.
- Trial name
- NCT04016844
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Iowa
Multiple Sclerosis
Natalizumab High Titer Immunogenicity and Safety
The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with…
- Trial name
- NCT00516893
- Testing
- BG00002-E (natalizumab high titer)
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Biogen
Multiple Sclerosis
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
The primary objective of the study is to assess the effect of long-term treatment with prolonged-release fampridine (BIIB041) 10 mg twice daily on the physical component scale (PCS) of the Short Form 36 Health Status…
- Trial name
- ENABLE (NCT01480076)
- Testing
- Fampridine
- Where
- 59 sites in Australia, Belgium and 7 more
- Volunteers
- 901 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04338061
- Testing
- Teriflunomide, Evobrutinib
- Where
- 278 sites in United States, Belarus and 30 more
- Volunteers
- 1,166 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis, Optic Neuritis
Ampyra for Optic Neuritis in Multiple Sclerosis
Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the hypothesis that dalfampridine, when administered to…
- Trial name
- NCT01337986
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis, Depression
Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication.
- Trial name
- NCT00122954
- Testing
- Fish oil concentrate
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Oregon Health and Science University
Progressive Multiple Sclerosis, Fatigue
A Study of Oxidative Pathways in MS Fatigue
This is a 4-week randomized, placebo-controlled, parallel group, double-blind, single center trial on effect of N-acetyl cysteine versus placebo on fatigue in patients with progressive MS defined by McDonald criteria.
- Trial name
- NCT02804594
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Parkinson's Disease, Multiple Sclerosis
Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Fatigue is one of the most common and debilitating symptoms experienced in Parkinson's Disease (PD) and Multiple Sclerosis (MS).
- Trial name
- PDMSLac (NCT02184494)
- Testing
- pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Florida State University
Multiple Sclerosis
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
To evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with RMS including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis…
- Trial name
- NCT03933202
- Testing
- Cladribine Tablets
- Where
- 66 sites in United States
- Volunteers
- 291 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing-Remitting Multiple Sclerosis
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- GLOW (NCT01578785)
- Testing
- Glatiramer Acetate
- Where
- 169 sites in United States, Albania and 17 more
- Volunteers
- 178 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.